Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients

References

• Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. Am J Hematol. 2017;92(9):879–884.
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40–48.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Hodgkin lymphoma: a 2020 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020;95(8):978–989.
   PubMed Web of Science ®Google Scholar
• LaCasce AS. Treating Hodgkin lymphoma in the new millennium: relapsed and refractory disease. Hematol Oncol. 2019;37(S1):87–91.
   PubMedGoogle Scholar
• Moskowitz AJ, Hamlin PA, Jr., Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456–460.
   PubMed Web of Science ®Google Scholar
• Abali H, Urün Y, Oksüzoğlu B, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest. 2008;26(4):401–406.
   PubMed Web of Science ®Google Scholar
• Choi Y, Diefenbach CS. Advances in therapy for relapsed or refractory Hodgkin lymphoma. Curr Oncol Rep. 2020;22(1):6.
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–2140.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Vitolo U, Viviani S, et al. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: experience with 27 patients. Clin Lymphoma Myeloma Leuk. 2015;15(7):404–408.
   PubMed Web of Science ®Google Scholar
• De Filippi R, Cillo M, Crisci S, et al. Continuous exposure to bendamustine (BDM) results in stable upregulation of CD30 and increased sensitivity to brentuximab vedotin (BV) in tumor cells of Hodgkin lymphoma (HL). Blood. 2015;126(23):2479–2479.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19(2):257–266.
   PubMed Web of Science ®Google Scholar
• Broccoli A, Argnani L, Botto B, et al. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the fondazione italiana linfomi. Blood Cancer J. 2019;9(12):100.
   PubMedGoogle Scholar
• Iannitto E, Romano A, Scalzulli PR, et al. Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. Eur J Haematol. 2020;104(6):581–587.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97–110.
   PubMedGoogle Scholar
• Picardi M, Della Pepa R, Giordano C, et al. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Adv. 2019;3(9):1546–1552.
   PubMed Web of Science ®Google Scholar
• Wagner SM, Melchardt T, Egle A, et al. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas. Eur J Haematol. 2020;104(3):251–258.
   PubMed Web of Science ®Google Scholar
• Sawas A, Ma H, Kuruvilla J, et al. Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. Leuk Lymph. 2020;61(12):3014–3017.
   PubMed Web of Science ®Google Scholar
• Pinczes LI, Szabo R, Illes A, et al. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma. Ann Hematol. 2020;99(10):2385–2392.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Długosz-Danecka M, Alekseev S, et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020;135(10):735–742.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Plütschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18(12):1680–1687.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642. Epub 2018 Sep 28.
   PubMed Web of Science ®Google Scholar
• Kersten MJ, Driessen J, Zijlstra JM, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC transplant BRaVE study. Haematologica. 2021;106(4):1129–1137.
   PubMed Web of Science ®Google Scholar
• Cassaday RD, Fromm JR, Cowan AJ, et al. Radiographic and high-throughput sequencing (HTS)-based response assessment after brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed/refractory (rel/ref) classical Hodgkin lymphoma (cHL): updated results of a phase I/II trial. Blood. 2017;130(Supplement 1):2806.
   Google Scholar
• Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood. 2017;130(26):2829–2837.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Ramchandren R, Santoro A, et al. KEYNOTE-204 investigators. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22(4):512–524. Epub 2021 Mar 12.
   PubMedGoogle Scholar